ATACANA GROUP Inc.’s Post

View organization page for ATACANA GROUP Inc., graphic

13,391 followers

✨ Unveiling the Next Era in MASH Treatment at the Upcoming European Association for the Study of the Liver (EASL) Congress 2024! We’ll be on the lookout for exciting updates from: 👉 Madrigal Pharmaceuticals' Resmetirom (Rezdiffra): how is the first and only approved MASH therapy setting new standards in liver health? What are the latest news on real-world evidence, non-invasive diagnostics, and patient quality of life improvements? 🔬 New Data and Discussion around other Promising MoAs: 🔴 GLP-1 Analogs: Semaglutide (Novo Nordisk) and Tirzepatide’s (Eli Lily) 🔴 Glucagon/GLP-1 receptor dual agonists: Survodutide (BI) and Pemvidutide (Altimmune) 🔴 FGF-21 Analogs: Efruxifermin (Akero) and Pegozafermin (89bio) 🔴 Other MoAs: Sagimet’s Denifanstat (FASN inhibitor) and Ionis’s ION224 (DGAT2 inhibitor) 💡 What breakthrough in MASH treatment are you most excited to see at EASL 2024? Share your thoughts in the comments section below 👇 For more insights on the MASH space, email us at info@atacana.com #EASL2024 #LiverHealth #MASH #NASH #PharmaInnovation #MedicalResearch #competitiveintelligence

Ankush Sharma

Market Analysis & Strategic Consulting I Pharma Forecasting I Healthcare Consulting

4mo

Also, advancements in NASH treatment include promising candidates like pegozafermin from 89bio, showing potential as a best-in-class option for non-alcoholic steatohepatitis (NASH). Additionally, Altimmune, Inc. has made significant progress with their treatments. These developments represent a forward leap in managing MASH effectively. Madrigal Pharmaceuticals' Resmetirom (Rezdiffra), the first and only approved MASH therapy, will definitely change the competitive landscape.

Garima Lour

Consultant at Atacana (Certified Scrum Master)

4mo

Interesting updates.. Please share..

See more comments

To view or add a comment, sign in

Explore topics